The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Wed., Oct. 22, 11:46 PM

Slide #23. Vital Therapies, Inc. Secondary Offering

Company: Vital Therapies, Inc. (NASDAQ:VTL)
Date announced: 9/30/2014
Shares Offered: 2,000,000
Date of Pricing: 10/2/2014
Price Per Share: $17.50
Secondary Offering Details: Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD, a cell-based therapy targeting the treatment of acute liver failure, today announced that it plans to commence an underwritten public offering of 2,500,000 shares of its common stock. In addition, Vital Therapies intends to grant the underwriters a 30-day option to purchase up to an additional 375,000 shares of its common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. - updated 10/3 - Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD, a cell-based therapy targeting the treatment of acute liver failure, today announced the pricing of its follow-on public offering of 2,000,000 shares of its common stock at a price to the public of $17.50 per share. In addition, Vital Therapies granted the underwriters a 30-day option to purchase up to an additional 300,000 shares of its common stock.

Vital Therapies is a developmental stage company. Co. is biotherapeutic company focused on developing a cell-based therapy targeting treatment of all forms of acute liver failure. Its product, the ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body, or extracorporeal, and is designed to allow the patient's own liver to regenerate to a healthy state, or to stabilize the patient until transplant. The ELAD System is the bio-artificial liver support system containing immortal human liver-derived cells, or C3A cells. Co. designs the ELAD System to supplement key aspects of normal liver function to improve patient survival.
Open the VTL Page at The Online Investor »

Company Name:  Vital Therapies Inc
Website:  www.vitaltherapies.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding VTL:  11
Total Market Value Held by ETFs:  $2.07M
Total Market Capitalization:  $354.00M
% of Market Cap. Held by ETFs:  0.58%
 

Open the VTL Page at The Online Investor (in a new window) »

October 22, 2014    11:46 PM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
93rd percentile
(ranked higher than approx. 93% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.